Risk of perioperative cardiorespiratory complications and mortality associated with preoperative glucagon-like peptide-1 receptor agonist use in type 2 diabetes mellitus. Comment on Br J Anaesth 2026; 136: 86–97

The study by Wu and colleagues presents a large-scale observational analysis using the TriNetX database to examine perioperative outcomes associated with glucagon-like peptide-1 receptor agonist (GLP-1 RA) use in patients with type 2 diabetes mellitus. The research benefits from a substantial sample size and comprehensive covariate adjustment. However, the authors highlight several methodological limitations that warrant careful consideration when interpreting the reported findings. The accompanying editorial effectively reframes the question of GLP-1 RA use in the perioperative period, though it may interpret these findings somewhat too enthusiastically.